BioSpace News Archive

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that clinical data from the Phase 2b STORM study evaluating the Company’s lead, oral Selective Inhibitor of Nuclear Export (SINE) compound selinexor in heavily pretreated patients with refractory multiple myeloma, has been selected for oral presentation at the Society of Hematologic Oncology (SOHO) 2018 Annual Meeting.

A Memorandum of Understanding (MOU) signed by Civilized and the University of New Brunswick (UNB) will guide their shared interests in cannabis research and public awareness.

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc. today announced that a Phase 3 study of flortaucipir F 18, a Positron Emission Tomography (PET) imaging agent, met its two primary endpoints, defined as predicting brain tau pathology and predicting Alzheimer’s disease diagnosis.

OncLive®, the leading digital provider of resources and information to oncology professionals, will host the latest State of the Science Summit™ on hematologic malignancies on Thursday, September 13 from 5- 9 p.m.(EDT) at the Henry, Autograph Collection in Dearborn, Michigan

An exciting medical technology that is FDA-cleared has been used by thousands of orthopaedic patients across the United States and is backed by strong scientific evidence.

Health Canada is advising Canadians that the following products may pose serious health risks.

Thomas Wirig Doll, a financial services firm specializing in providing dentists and physicians with wealth, tax, accounting, retirement and pension advice, today announced a name change to Thomas Doll.

In the newest rounds of grants marking its 20th anniversary, Hyundia Hope of Wheels 501(c)(3), celebrates National Childhood Cancer Awareness Month awarding Dr. Darrell Yamashiro of Columbia University Irving Medical Center with a $2.5 million Hyundai Quantum grant.

AcuityBio Inc., a developer of novel drug-delivery, combination products, announced that it has entered into agreements with Cook Biotech Inc., a leader in advanced biomaterials and regenerative medicine.

Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced that the Company will present at the following investor conferences.